Aleksandra Rizo, M.D., Ph.D., joined Vividion in 2022 as President and Head of Research and Development. In 2023 Dr. Rizo was promoted to President and Chief Executive Officer and joined the Board of Directors of Vividion. Previously, Dr. Rizo served as Executive Vice President and Chief Medical Officer of Geron Corporation since where she provided leadership and direction for all clinical and translational efforts. Included in her reporting responsibilities were clinical development, clinical operations, clinical pharmacology, biometrics, translational research, program management and medical affairs. Prior to joining Geron, Dr. Rizo was Strategy and Clinical Lead, at Celgene Corporation where she led submission activities which resulted in successful NDA and MAA approvals, and participated in strategic development activities in the Myeloid Therapeutic Area. From 2008 to 2018, Dr. Rizo served in a number of oncology drug development functions with increasing responsibilities at Janssen Research and Development, LLC (Janssen), including Senior Director, Compound Development Team Leader for the myeloid portfolio, Senior Director, Global Clinical Leader for multiple assets, including imetelstat, ibrutinib mantle cell lymphoma (MCL), and others. In these roles, she had oversight and leadership responsibilities for clinical development strategy, execution and regulatory submission activities. In addition, Dr. Rizo was a core member of Janssen’s Hematology Strategy Team where she participated and led multiple diligence projects. Dr. Rizo earned an M.D. degree from the University Ss Cyril and Methodius, Skopje, Macedonia, where she also completed a residency in internal medicine/hematology. Dr, Rizo obtained her Ph.D. degrees in Stem Cell Biology from the University of Groningen in the Netherlands, and the University of Tokyo, in Japan.